Variational AI, a generative AI drug discovery company, has announced a collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to use Variational AI’s Enki™ platform. The company plans to use a version of its Enki™ platform trained on MSD’s proprietary data to generate and optimize small molecule development against two undisclosed therapeutic targets. The agreement includes that MSD will have exclusive rights to develop and commercialize compounds resulting from this collaboration.
